Business Wire

May Health Solidifies Veteran Executive Team with Appointment of Women’s Health Care Leader Anne Morrissey as CEO

Share

May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it is changing its name from AblaCare to May Health, and has solidified its executive team with Anne Morrissey as CEO and Dr. Robert Auerbach, OBGYN, as chairman of the board. Morrissey, an experienced executive who was previously CEO of Alydia Health, will lead May Health as it investigates its novel Ovarian Rebalancing™ technology, a one-time, transvaginal ablation procedure designed to activate natural ovulation for those with PCOS, a leading cause of infertility.

“With Anne and Bob, May Health is guided by some of the most respected and accomplished leaders in the women's health care ecosystem,” said Antoine Papiernik, chairman and managing partner at Sofinnova Partners, and the previous chairman of May Health. “Anne is an experienced executive and team builder who has devoted her career to making pregnancy and childbirth safer and more accessible. As an OBGYN and retired president of CooperSurgical, Bob brings both clinical and operational expertise to the board. With their leadership, May Health is well positioned to enter a new phase of growth to develop and commercialize life-changing solutions for those living with PCOS.”

May Health’s proprietary technology, Ovarian Rebalancing, is an investigational treatment designed to start a woman’s natural ovulation cycle, allowing for the opportunity to become pregnant. It is an ultrasound-guided, transvaginal ablation procedure similar to egg retrieval that utilizes radiofrequency (RF) energy to establish regular menstrual cycles. Ovarian Rebalancing is a one-time, in-office procedure intended to allow for same-day recovery and return to normal activities. It is currently being investigated in a European clinical study and a U.S. feasibility study.

“Those with PCOS face significant health challenges and frustrations every day, from symptoms like weight gain and acne to irregular menstrual cycles and life-altering complications around ovulation and fertility,” said Dr. Auerbach. “The current fertility treatment landscape can be just as distressing for patients with concerns regarding cost, access, and the complexity of in vitro fertilization (IVF), along with side-effects of gonadotropins. Our goal is to develop a safe, simple procedure that activates natural ovulation for women living with PCOS. Ovarian Rebalancing has the potential to fill that need and help thousands of women regain the option to have children and start families, and we look forward to continuing to enroll patients in our clinical trials to demonstrate these benefits.”

“I joined May Health to change the outlook for people living and struggling with the negative effects of PCOS,” said Morrissey. “Restoring ovulation is our current focus, but our technology may also have the potential to address the underlying endocrine disorder. Our new name reflects this overarching commitment to helping women overcome PCOS and experience new beginnings and opportunities. I’m excited to lead and build a team that has the experience, passion, and empathy needed to improve the PCOS outlook for millions of women.”

About Polycystic ovary syndrome (PCOS)

Polycystic ovary syndrome (PCOS) is a common endocrine condition where the ovaries produce abnormal levels of androgens, which are male sex hormones that are usually present in women in small amounts.1 In many cases, those with PCOS are unable to produce enough of the hormones needed to ovulate and become pregnant, which can lead to the development of ovarian cysts.1 PCOS is one of the most common causes of female infertility, affecting roughly 6 to 12% of U.S. women of reproductive age.2 PCOS is also a lifelong challenge that goes beyond fertility issues. Women with PCOS are often insulin resistant, increasing their risk for Type 2 diabetes; more than half of PCOS sufferers will develop Type 2 diabetes by age 40 and they are also at increased risk of heart disease and stroke.2 Other common, persistent symptoms of PCOS include irregular menstruation, acne, thinning scalp, excess hair growth on the face and body, high blood pressure, and sleep apnea.2

About Anne Morrissey

Anne Morrissey is an experienced entrepreneur, executive, and advisor who has led numerous medical device companies dedicated to women’s and maternal health care. Anne’s lifelong passion for making childbirth and motherhood safer and more accessible has led to leadership and advisory roles in numerous companies. She is the former Chair, President and CEO of Alydia Health, and serves as director of Femasys Inc.; she previously served as vice president of Astia; as co-founder and director of Vivant Medical; and as entrepreneur in residence of UCSF Innovation Ventures. Anne is a gifted team builder and manager who has led various exits, transitions, and global partnerships; she is an advisor to several prominent medtech CEOs and was named one of the 100 Women of MedTech in 2019.

About Dr. Robert Auerbach

Dr. Robert “Bob” Auerbach, OBGYN, has exemplified commitment to women’s and maternal health over a distinguished 35+ year career that includes both clinical practice and extensive experience running large healthcare companies. Dr. Auerbach served as the chief medical officer, chief strategy officer, and ultimately president of CooperSurgical, a wholly owned subsidiary of The Cooper Companies specializing in women’s healthcare and fertility treatments. He serves as the chairman of the board for Escala Medical, and as a board member for OCON Healthcare, Aspira Women’s Health, Empress Medical, and the Yale University Center for Biomedical Innovation and Technology. Dr. Auerbach is a graduate of the Lehigh-Hahnemann/Drexel 6-year BA-MD program and completed his OB/GYN residency at Yale, where he currently serves as an adjunct member of the medical school faculty.

About May Health

May Health, formerly AblaCare, is a clinical-stage medical device company committed to developing more treatment options for people living with PCOS. The company is currently investigating its Ovarian Rebalancing™ technology in clinical studies; Ovarian Rebalancing is a novel approach to PCOS-related fertility issues that has the potential to be a safe, relatively simple option for activating natural ovulation. May Health is led by a team of serial medtech and women’s health entrepreneurs and executives with extensive experience in product development, validation, and launch. The company has raised €10M in a Series A led by Sofinnova Partners and was founded in 2017 by the firm’s medtech acceleration team, Sofinnova MD Start. May Health is headquartered in Paris, France. For more information, visit www.mayhealth.com.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, visit: sofinnovapartners.com.

____________________
1
Johns Hopkins Medicine
2CDC

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Jenna Kane
(480) 388-9587
jennakane@healthandcommerce.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest Launches The Phoenix Project, an Employee Resource Group for Women28.3.2024 16:00:00 CET | Press release

LambdaTest, a leading cloud-based unified testing platform, announced the launch of The Phoenix Project, an Employee Resource Group (ERG) dedicated to supporting and promoting the success of its female employees. “LambdaTest is committed to fostering a diverse, inclusive, and equitable workplace where all employees feel valued and empowered to reach their full potential,” said Chandini Chopra, VP of People and Culture at LambdaTest. “The Phoenix Project is a critical step towards achieving this goal by providing a platform for professional development, networking, and mentorship, especially for our women employees.” The Phoenix Project Aims To: Offer professional development workshops, networking opportunities, and dedicated time off for women to participate in ERG initiatives. Provide mentorship programs connecting senior female employees with mentees. Promote leadership development among women within the company. Create a sense of community for women in the workplace. Leadership and

The reopening of the Yokohama Museum of Art adds another innovative and distinctive venue for events in Yokohama28.3.2024 16:00:00 CET | Press release

After extensive renovations, the iconic Yokohama Museum of Art has reopened its doors to visitors from all over the world. The museum’s reopening paves the way to new and closer collaboration with international events in Yokohama. This extraordinary venue is the ideal setting for a one-of-a-kind gathering, in part, supported by the Yokohama Convention & Visitors Bureau (hereinafter YCVB). The Yokohama Museum of Art Founded in 1989, the Yokohama Museum of Art collects over 14,000 works of art that reflect the many facets of life in Yokohama—past, present, and future. The reopening of the museum coincides with the Yokohama Triennale, an international exhibition featuring contemporary artists whose decentralized exhibits turn the entire metropolis into an art museum. The 8th Yokohama Triennale is being held from March 15 to June 9, 2024, with the Yokohama Museum of Art being a pivotal venue for the exhibition. With the museum firmly back on the map as Yokohama’s leading artistic venue, YC

Eight new sustainability-themed experiences—exclusive to Yokohama—for convention participants28.3.2024 16:00:00 CET | Press release

In a survey conducted by Yokohama Convention & Visitors Bureau (hereinafter YCVB), many convention attendees expressed particular interest in Yokohama’s culture, sightseeing spots, and local cuisine. In response, YCVB has developed eight new Yokohama Tours for event attendees to enjoy during their free time in Yokohama, keeping in line with our ethos of sustainability. Noge Area Bar-Hopping Tour, complete with guide Known affectionately by locals as Yokohama’s kitchen, Noge is a bustling nightlife spot that is home to over 600 izakaya (Japanese-style pubs). A knowledgeable local guide will lead participants to all the hidden gems in Noge, where they can indulge in distinctive, delicious pub-style food and drink. With easy on-foot accessibility, participants can rest assured this fun night out won’t impact their carbon footprint. Soto Zen Tour of Sojiji, head temple of the Soto Zen school As a prominent Zen sect in Japan, Soto Zen provides one of the best Zen wellness experiences. Durin

Nordson EFD Releases New 3-Axis Automated Fluid Dispensing Systems28.3.2024 15:00:00 CET | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer is proud to announce the new GVPlus and PROX families of automated fluid dispensing products. Both robotic solutions share a focus on motion, workspace, repeatability, payload, setup, and vision technology enhancements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305726899/en/ The GV Series offers market-leading dimensional positional accuracy and deposit placement repeatability. (Photo: Business Wire) The new GVPlus automated fluid dispensing solution offers improved repeatability, bigger payloads with simplified setup requirements, and superior vision capabilities. Repeatability is now best-in-class at 8 μm, improving repeatability to ±0.008 mm. Setting up the robot is easier due to a new dual mounting flange that enables a tool payload of up to 4.5 kg (10 lbs). When paired with the working area of 400 mm x 400 m

Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft28.3.2024 14:00:00 CET | Press release

Kolmar Korea (KRX:161890), a Korean cosmetics ODM (Original Development Manufacturing) company, has announced its victory in a lawsuit against Intercos Korea, the Korean subsidiary of the Italian cosmetics maker, Intercos. Intercos was revealed to have misappropriated and profited from the key technology for suncare (sunscreen) products, originally developed by Kolmar Korea. Kolmar Korea had invested hundreds of billions of KRW in this technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328015022/en/ Kolmar Korea wins the case against Italian cosmetics maker Intercos for stealing suncare technology (Kolmar Korea R&D Complex) (Photo: Kolmar Korea Holdings) Kolmar Korea took legal action for 'trade secret infringement' against its former employees who have leaked the technology and Intercos Korea, resulting in favorable rulings in both civil and criminal cases. The Korean courts ordered Intercos Korea to pay KRW 200

HiddenA line styled icon from Orion Icon Library.Eye